Acquisition of complement-dependent cytotoxicity by type II anti-CD20 therapeutic antibody obinutuzumab

Kuzniewska, A; Majeranowski, A; Kowalska, D; Urban, A; Henry, S; Okroj, M

MOLECULAR IMMUNOLOGY, 2022; 141 (): 122